Keyword: upadacitinib (ABT-494)
JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.
The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.
AbbVie is suffering from Humira biosims in Europe, but new launches could help the company backfill those losses—and Skyrizi's new numbers show how.
Even as AbbVie’s industry-leading Humira faces its eventual sales decline, the company can be thankful that it has two out of the three top launches of 2019, based on 2024 sales.
AbbVie is rolling out psoriasis drug Skyrizi after an approval last month, and it's offered Humira discounts in payer negotiations to support the launch, an analyst writes.
AbbVie's Humira just posted its first-ever drop in worldwide sales—and with biosimilars on the march in Europe, it's not likely to be the last.
A new investigative report outlines how AbbVie worked to keep Humira market share upon the introduction of biosimilars in the Netherlands.
Pfizer has run into safety issues with Xeljanz. But whether the issues belong to the drug—rather than to its burgeoning class—remains to be seen.
The benefits of the upcoming tax overhaul will be so great that AbbVie is planning $2.5 billion in capital projects in the U.S.